Although the major anti-cancer effects of blocking programmed cell death 1 (PD-1) and PD-L1 interactions in vivo are driven by the marked upregulation of anti-cancer adaptive immune responses, several studies have reported that PD-L1 also triggers intrinsic carcinogenic signaling independent of the immune checkpoint pathway [46,47]. Here, PDCD1 is linked to cancer.